www.autolus.com Open in urlscan Pro
2606:4700:10::6816:2bd3  Public Scan

Form analysis
1 forms found in the DOM

GET /search

<form action="/search" method="GET">
  <label class="visually-hidden" for="query">Search</label>
  <input type="search" placeholder="Search..." name="query" id="query" value="">
  <button aria-label="Search">
    <svg class="svg-inert" viewBox="0 0 55 55">
      <g fill="none" fill-rule="evenodd">
        <circle fill="#5DE585" cx="27.5" cy="27.5" r="27.5"></circle>
        <path class="cta__1" d="M42.58 27.01 35.4 19.8a.9.9 0 0 0-1.28 1.27l5.61 5.66H13.28a.9.9 0 1 0 0 1.8h26.5l-5.7 5.66a.9.9 0 0 0 1.27 1.28l7.22-7.17a.9.9 0 0 0 0-1.28Z" fill="currentColor" fill-rule="nonzero"></path>
        <path class="cta__2" d="M42.58 27.01 35.4 19.8a.9.9 0 0 0-1.28 1.27l5.61 5.66H13.28a.9.9 0 1 0 0 1.8h26.5l-5.7 5.66a.9.9 0 0 0 1.27 1.28l7.22-7.17a.9.9 0 0 0 0-1.28Z" fill="currentColor" fill-rule="nonzero"></path>
        <path class="cta__3" d="M42.58 27.01 35.4 19.8a.9.9 0 0 0-1.28 1.27l5.61 5.66H13.28a.9.9 0 1 0 0 1.8h26.5l-5.7 5.66a.9.9 0 0 0 1.27 1.28l7.22-7.17a.9.9 0 0 0 0-1.28Z" fill="currentColor" fill-rule="nonzero"></path>
        <path class="cta__4" d="M42.58 27.01 35.4 19.8a.9.9 0 0 0-1.28 1.27l5.61 5.66H13.28a.9.9 0 1 0 0 1.8h26.5l-5.7 5.66a.9.9 0 0 0 1.27 1.28l7.22-7.17a.9.9 0 0 0 0-1.28Z" fill="currentColor" fill-rule="nonzero"></path>
      </g>
    </svg>
  </button>
</form>

Text Content

 * Content
 * Search
 * Navigation
 * Sitemap

Menu

 * Home
 * About us
   * Overview
   * Our purpose
   * Our partners
   * Leadership
   * Our history
   * Culture and values
 * Technology
   * Overview
   * Chimeric Antigen Receptor T Cell therapy
   * Advanced cell programming
   * Manufacturing
   * Abstracts & publications
 * Pipeline
   * Overview
   * Our products
   * Obe-cel

 * Information for patients
   * Overview
   * Obe-cel in Adult ALL - The Felix Study
   * Our Clinical Trials
   * Patient Care Guides
 * Careers
 * Investor relations
   * Overview
   * News
   * Events
   * SEC filings
   * Quarterly earnings
   * Stock & quote chart
   * Historical price lookup
   * Investment calculator
   * Analyst coverage
   * Corporate governance
   * Corporate presentations
   * AGM
   * Investor FAQs
   * Investor contacts
   * Email alerts
 * Contact us

Search


DEVELOPING LIFE-CHANGING TREATMENTS FOR CANCER PATIENTS

Corporate presentations



TRANSFORMING TREATMENTS FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

About Obe-cel



CLINICAL-STAGE PROGRAMS FOR HEMATOLOGICAL AND SOLID TUMOR INDICATIONS

Our pipeline



DEVELOPING LIFE-CHANGING TREATMENTS FOR CANCER PATIENTS

Corporate presentations



TRANSFORMING TREATMENTS FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

About Obe-cel

1 / 3


WHO WE ARE

Autolus is a CAR T cell therapy company. We are applying our extensive
programing capabilities to develop advanced autologous T cell therapies that
have the potential to deliver life-changing benefits to cancer patients

About us


OUR TECHNOLOGY

 * Chimeric Antigen Receptors
 * Advanced Cell Programing
 * T Cell Manufacturing


CHIMERIC ANTIGEN RECEPTORS

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product
candidates. These receptors combine the tumor recognition domain of an antibody
with the activation and costimulatory domains from the T cell receptor to rearm
a patient’s T cells to recognize and kill their cancer cells.


ADVANCED CELL PROGRAMING

Autolus is applying its extensive cell programing capability to develop a
pipeline of precise, controlled and highly active products.


T CELL MANUFACTURING

We have developed our own proprietary viral vector and semi-automated cell
manufacturing processes to engineer a patient's T cells with the CAR and other
advanced cell programing modules.


Explore our technology




OBE-CEL

The company’s lead therapeutic candidate, obe-cel, is a transformational
treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19
CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a
“fast-off” kinetic which mimics physiological T cell receptor interactions.
Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile
results in increased T cell persistence leading to high levels of durable
remissions and remarkably low levels of cytokine release syndrome and other
immunotoxicities. Obe-cel is currently being evaluated in the potentially
pivotal FELIX study in adult ALL and in phase 1 studies for other B-NHL
indications.

Find our more



OUR OBE-CEL ABSTRACTS AND PUBLICATIONS

See all
American Society of Hematology Annual Meeting
December 13 2021


SAFETY AND EFFICACY OF AUTO1, A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY
B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

American Society of Hematology Annual Meeting
December 12 2021


INDUSTRIALIZATION OF AN ACADEMIC MILTENYI PRODIGY-BASED CAR T PROCESS

Journal of Clinical Oncology
August 04 2021


DURABLE RESPONSES AND LOW TOXICITY AFTER FAST OFF-RATE CD19 CAR-T THERAPY IN
ADULTS WITH RELAPSED/ REFRACTORY B-ALL


LATEST NEWS

Get the latest updates from Autolus on new research, company news and events

View all news




INFORMATION FOR PATIENTS

Clinical trials are required to gain regulatory approval for new medicines to
advance patient care.

Learn more about our CAR T cell therapy clinical trials



LIFE AT AUTOLUS

Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working
environment which actively promotes creativity, leadership and teamwork –
together we are ONE Autolus.

Careers at Autolus



INVESTORS

Autolus is committed to the development and commercialization of obe-cel in r/r
Adult ALL and is progressing opportunities for obe-cel in additional indications
alongside its preclinical and clinical pipeline for hematological malignancies
and solid tumors.

View investor information

 * About us
 * Technology
 * Pipeline
 * Information for patients
 * Careers
 * Investor relations
 * Contact us

 * LinkedIn

 * Terms of use
 * Privacy & cookies
 * Accessibility
 * Copyright © 2022 Autolus Therapeutics. All Rights Reserved.

Designed & built by SampsonMay



Close


We use cookies to make our website work more efficiently, to provide you with
more personalised services, and to analyse traffic on our website. For more
information on how we use cookies and how to manage cookies, select 'Cookie
settings'.

 * Cookie settings
 * Accept & close

 * Necessary
 * Performance

Save preferences